Activating the Value of RWD/RWE in a COVID-19 World

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
As the industry continues its shift from volume to value, stakeholders are increasingly relying on the power of data, specifically real-world data (RWD), to evaluate drug value. This has made it imperative for manufacturers to consider how best to bring the value of their products to life earlier in the product life cycle. Key industry stakeholders will discuss their plans to expand the innovation horizon and plans to not only leverage technology to support real-world-data collection, but also seek alternative channels and platforms for data capture.
Moderator
photo
Managing Director
EY
Speakers
photo
Medical Director
HealthNet
photo
Head, Patient Strategies & Solutions
Janssen
photo
Global Chief Medical Officer (CMO) and VP of Healthcare
Microsoft
photo
Managing Director
EY
photo
Payer Insights and Access Regional Cluster Lead - North America
Pfizer